...
GET IN TOUCH

Molecules to Medicines

End-to-End CRDMO Solutions Powered by Digital & AI

Meet us at CPHI Milan 2026

Date: October 06-08, 2026 | Location: Milan

Booth No: 10K9

Advancing Small & Large Molecules from Concept to Commercialization

Today’s pharma innovators face growing complexity across therapeutic modalities, development timelines, regulatory demands, and supply chain resilience. Success requires a partner with the right expertise, capabilities, and agility.

Aragen delivers end-to-end CRDMO solutions for small molecules, biologics, peptides, oligonucleotides, ADCs, and next-generation therapeutics. Our integrated discovery, development, manufacturing, and analytical capabilities ensure a seamless path from early research to commercial supply, reducing risk and accelerating time to market.

Powered by deep scientific expertise, advanced infrastructure, and Digital & AI-enabled insights, we deliver with a steadfast commitment to quality, sustainability, and supply chain resilience to bring life-changing therapies to patients faster.

Book a Meeting with Our Experts

Explore Our Integrated Capabilities

SMALL MOLECULES

Taking Molecules from Process Design to Commercial Reality

Successful small molecule programs demand scalable processes, reliable manufacturing, integrated formulation development, and analytical excellence. Aragen supports customers across the entire development continuum—from route selection and process optimization to seamless tech transfer, analytical development, clinical supply, commercial manufacturing, and lifecycle management.

Learn More →

LARGE MOLECULES

From Cell Line to Commercial Supply—Without Losing Momentum

Biologics development requires seamless alignment across cell line development, process characterization, analytical development, manufacturing scale-up, tech transfer, and regulatory readiness. Aragen’s integrated biologics platform supports monoclonal antibodies, biosimilars, bispecifics, and other complex biologics—minimizing complexity and maintaining quality, scalability, and speed throughout development.

Learn More →

Emerging Modalities

Supporting the next generation of therapeutics through specialized scientific expertise and scalable development strategies

Oligonucleotides

Oligonucleotides

From early development to manufacturing support, leveraging expertise in phosphoramidite chemistry, process optimization, analytical characterization, and scalable production.

Peptides

Peptides

Integrated solutions for peptide development, scale-up, analytical support, and manufacturing.

ADCs

ADCs

Support for payloads, linkers, and complex chemistries through dedicated scientific teams and high-containment infrastructure.

Next-Generation Therapeutic

Next-Generation Therapeutic

Capabilities supporting advanced biologics, targeted therapies, and other emerging therapeutic platforms.

Resilient Networks. Operational Excellence. Sustainable Outcomes.

At Aragen, supply chain resilience is powered by diversification, localization, digitalization, and operational excellence—helping ensure your molecules reach patients reliably, efficiently, and responsibly.

...

Hyper-Local & Diversified Sourcing

  • 42% of sourcing is hyper-local (within 200 km)
  • Reduced import dependency from ~60% to ~10% over five years
  • 54% supplier diversity supported by rigorous performance assessment

...

Sustainability at the Core

  • EcoVadis score of 80 (Top 1% globally)
  • CDP A-List recognition for supplier engagement
  • Sustainable Aviation Fuel (SAF) adoption and green logistics initiatives
  • Scorecard-based sustainability assessments across suppliers and internal teams

...

Digitally-Driven Efficiency

  • Fully digitalized Source-to-Pay ecosystem (SAP Ariba & S/4HANA)
  • AI-enabled sourcing and RPA-automated workflows
  • Real-time shipment tracking and visibility
  • E-auctions and global compliance screening

...

Global Coordination Advantage

  • US time-zone operations supporting seamless India–US collaboration
  • EOU and SEZ advantages for agile delivery
  • Strategic logistics partnerships ensuring supply continuity

Why Global Innovators Choose Aragen

...

Integrated CRDMO Model. Fewer Handoffs. Greater Continuity.

From discovery through commercial manufacturing, Aragen brings together discovery, development, manufacturing, and analytical services under one roof—reducing complexity, minimizing technology transfer risks, and improving program continuity.

Expertise Across Molecules and Modalities

Deep scientific expertise spanning small molecules, biologics, peptides, oligonucleotides, ADCs, high-potency compounds, and complex chemistries enables customers to advance diverse pipelines with confidence.

Built to Scale with Your Program

Flexible capabilities support every stage of development—from early discovery and clinical development to commercial manufacturing and lifecycle management.

Quality and Compliance Built into Every Stage

Robust quality systems, regulatory readiness, and a strong culture of operational excellence underpin development and manufacturing activities across our global network.

Global Infrastructure, Collaborative Execution

Integrated scientific teams, GMP manufacturing facilities, and supply chain capabilities across geographies provide the flexibility, reliability, and responsiveness needed to support global development programs.

Customer-Centric Partnerships

Flexible engagement models and dedicated project teams aligned to your scientific, operational, and strategic objectives

Talk to Our Experts

  • Clinical Development Strategies
    Tailored approaches to accelerate your path to the clinic.
  • Commercial Manufacturing
    Reliable, scalable solutions for seamless commercial supply.
  • Biologics Scale-Up
    End-to-end expertise from cell line to commercial scale.
  • Oligonucleotide Programs
    Specialized capabilities for complex oligonucleotide modalities.
  • ADC Opportunities
    Conjugation expertise across diverse linker-payload platforms
  • Tech Transfer
    Seamless technology transfer designed to protect program continuity and timelines.
  • Process Intensification & COGS Improvement for Biologics
    Advanced bioprocessing strategies to enhance yield, efficiency, and scalability while driving meaningful cost savings.
  • Integrated DS-DP with Analytical Excellence
    End-to-end drug substance and drug product development backed by robust analytical capabilities.
  • Supply Chain Optimization
    Resilient, end-to-end solutions built for reliability and continuity.

Schedule a Meeting at CPHI Milan 2026

Comprehensive small molecule development and manufacturing solutions supporting programs from discovery through commercialization.

  • Route scouting, optimization, and technology transfer
  • Phase-appropriate process and analytical development
  • QbD and DoE-based scale-up strategies
  • 600+ m³ of total reactor volume across 5 GMP-certified sites
  • 360 KL reactor capacity across 3 globally accredited sites
  • Support for 100+ preclinical-to-commercial programs annually
  • 300+ chemists and engineers across process R&D and analytical functions
  • Proven track record in seamless scale-up to clinical and commercial launch
  • Accredited by USFDA, EMA, WHO, PMDA, and ISO
  • Comprehensive support from pre-formulation to clinical drug product development and manufacturing
  • Salt screening, polymorph screening, and preclinical formulations
  • Bioavailability enhancement solutions including SDDs, nano-suspensions, emulsions, and oral peptide delivery
  • Broad dosage-form expertise encompassing oral solids, injectables, topicals, and long-acting injectables
  • State-of-the-art cGMP formulation facility supporting diverse clinical trial requirements
  • Method development and validation including nitrosamine and genotoxic impurity profiling
  • Extractables and leachables characterization
  • Microbiology, dissolution, sterility, BET, and kill-rate studies
  • cGMP stability and photostability programs
  • Advanced instrumentation including LC-MS/MS, GC-MS, ICP-MS, QTOF, and Orbitrap
  • Regulatory excellence with extensive GMP inspection experience and global accreditations
  • Clinical drug product manufacturing and integrated DS/DP solutions
  • Clinical and commercial production of APIs and intermediates
  • Batch sizes ranging from gram-scale to multi-ton scale
  • Expertise in non-GMP/GMP KSMs, intermediates, and APIs
  • Integrated DS/DP manufacturing enabling accelerated clinical progression
  • Development of early-phase (FIH) and late-phase (2B) clinical drug products
  • Digital QC laboratories with LIMS-enabled operational transparency
  • Multi-site operations in India and the US for supply continuity
  • Golden Batch Analytics powered by AI/ML
  • HPAPIs and cytotoxic compounds in dedicated high-containment suites
  • Flow chemistry, biocatalysis, and process safety expertise
  • Complex chemistries including peptides, oligonucleotides, and ADC payloads
  • Spray drying and nanotechnology solutions from development to GMP manufacturing

Talk to Our Small Molecule Experts

Let’s discuss how to create a development and manufacturing strategy that supports your molecule from process design through commercial launch.

Schedule a Meeting at CPHI Milan 2026

Integrated biologics discovery, development, manufacturing, and analytical solutions designed to enable next-generation therapies.

  • CHOMax™ with Fut∞KO glycoengineered platform supporting enhanced ADCC and cost-efficient therapeutic development
  • Up to 8 g/L single-cell clone titers within 16 weeks
  • Greater than 25 g/L productivity following N-stage intensification
  • Royalty-free CHO DG44 and CHO GS platforms
  • Successful execution of 200+ cell line development projects
  • High-throughput antibody screening and monoclonality assessment using Cytena and Solentim technologies
  • Transient and stable expression systems across CHO, HEK, Expi, and hybridoma platforms
  • Advanced biochemical and biophysical characterization capabilities
  • Platform and customized analytical methods
  • Method qualification and validation aligned with regulatory requirements
  • Formulation development and stability studies
  • Stress testing including pH, agitation, freeze-thaw, and photostability
  • Biosimilar comparability expertise
  • GMP and non-GMP stability support
  • Advanced analytical instrumentation and characterization expertise supporting product quality and regulatory submissions
  • Gene synthesis to protein delivery from mg to kg scale
  • Wave, bench-top, and single-use bioreactor systems (50L–250L)
  • GMP manufacturing at 200L, 500L, and 2,000L scales
  • Commercial manufacturing capacity expandable to 23 KL
  • Minimum titers of 4 g/L for most mAbs and BsAbs
  • Productivity up to 25 g/L through process intensification
  • Expertise spanning mAbs, bispecifics, trispecifics, fusion proteins, enzymes, and receptor proteins
  • ISO 9001-certified facility
  • Perfusion technologies supporting seed intensification and production processes
  • Virus clearance studies utilizing robust scale-down models
  • Material equivalency assessments
  • Process intensification studies to optimize productivity
  • Dedicated AHUs and comprehensive contamination mitigation strategies
  • Support for complex biologics and next-generation therapeutic formats

Talk to Our Biologics Experts

Whether you’re developing a monoclonal antibody, biosimilar, bispecific, fusion protein, or emerging biologic modality, Aragen can help establish a development and manufacturing pathway designed for scalability, quality, and long-term supply success.

Schedule a Meeting at CPHI Milan 2026

Aragen’s Leadership Presence at CPHI

Meet our team of experts who will be present at CPHI Milan 2026.
Connect with us to discuss your drug development challenges.

img

Ashu Tandon

Chief Commercial Officer

in

img

Aniel Khubchandani

CEO, Development & Manufacturing Solutions

in

img

Subodh Deshmukh

CEO, Biologics Solutions

in

img

Jayadeva Sajankila

VP & Head, Chemical Development Solutions

in

img

Vaibhav Sihorkar

VP & Head, Formulations Solutions

in

img

Ramesh Jagadeesan, PhD

VP & Business Unit Head – Analytical Solutions

in

img

Yogesh Kumar Jain

VP and Business Unit Head, Custom Manufacturing Solutions

in

img

Srinivas Reddy Mamidi

Business Development, Global Head – Key Accounts

in

img

Amar Karandikar

SVP and Global BD Head, Small Molecule Development and Manufacturing

in

img

Keshav Vasanthavada

Global Head of Business Development, Biologics Services

in

img

Christina Dreher

Director, Small Molecule Development and Manufacturing

in

img

Maheshwar M. Bole

Associate Director, Custom Manufacturing Solutions

in

img

Sumaiya Khan

General Manager, Small Molecule Development and Manufacturing

in

Seraphinite AcceleratorOptimized by Seraphinite Accelerator
Turns on site high speed to be attractive for people and search engines.